Eosinophilia resulting from administration of recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in a patient with T-gamma lymphoproliferative disease.
A therapeutic trial of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was attempted in a patient with neutropenia and frequent infections secondary to T-gamma lymphoproliferative disease (T-gamma LPD). During the 14 days of subcutaneous rhGM-CSF (500 micrograms/m2/day), the absolute eosinophil count increased from 0 to 9,455/microliters. By contrast, the absolute neutrophil count decreased. Toxicity related to rhGM-CSF included arthralgia and nonspecific chest pain. The possible mechanism for the rhGM-CSF induced selective eosinophilia is discussed.
Gonzales-Chambers
R
R
Department of Internal Medicine, University of Pittsburgh, School of Medicine, Pennsylvania.
Rosenfeld
C
C
Winkelstein
A
A
Dameshek
L
L
D000328:Adult; D004802:Eosinophilia / Q000209:etiology* / Q000473:pathology; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D007279:Injections, Subcutaneous; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D009504:Neutrophils / Q000473:pathology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D013601:T-Lymphocytes / Q000473:pathology
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor